Resources from the same session
4597 - Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407
Presenter: Steven Powell
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
3850 - Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC
Presenter: Tony S.K. Mok
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
6131 - Safety and efficacy of WX-0593 in ALK-positive or ROS1-positive non-small cell lung cancer
Presenter: Yuan-Kai Shi
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
1906 - Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients
Presenter: Steffie Groenland
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
2577 - Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting
Presenter: D. Ross Camidge
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
4178 - Entrectinib in Locally Advanced/Metastatic ROS1 and NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC): Updated Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo Guglielmo De Braud
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
4899 - Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: results of the prospective PFROST trial
Presenter: Lorenza Landi
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
1857 - A Phase 1a/2a Trial of Sym015 - a MET Antibody Mixture - in Patients with Advanced Solid Tumors
Presenter: D. Ross Camidge
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
4134 - Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407
Presenter: Luis Paz-Ares
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
Slides
2239 - Final efficacy results from B-F1RST, a prospective Phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
Presenter: Mark Socinski
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract